In the BioHarmony Drug Report Database

"Preview" Icon

Vortioxetine

Trintellix, Brintellix (vortioxetine) is a small molecule pharmaceutical. Vortioxetine was first approved as Trintellix on 2013-09-30. It is used to treat major depressive disorder in the USA. It has been approved in Europe to treat major depressive disorder. The pharmaceutical is active against 5-hydroxytryptamine receptor 1B, 5-hydroxytryptamine receptor 7, 5-hydroxytryptamine receptor 1A, and sodium-dependent serotonin transporter. In addition, it is known to target 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 3A, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 5A, and 5-hydroxytryptamine receptor 1D. Trintellix’s patents are valid until 2032-03-21 (FDA).

 

Trade Name

 

Brintellix
 

Common Name

 

vortioxetine
 

ChEMBL ID

 

CHEMBL2104993
 

Indication

 

major depressive disorder
 

Drug Class

 

Antidepressants (fluoxetine type): thioether derivatives

Image (chem structure or protein)

Vortioxetine structure rendering